Tilray Brands
Global cannabis and consumer goods company. Largest cannabis company by revenue globally with operations in 20+ countries.
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
Tilray Brands earns a Neutral rating with a composite score of 49.45, reflecting balanced strengths in its Canadian regulatory environment against persistent operational headwinds and absent market liquidity. The company operates from a jurisdiction rated at 80 on regulatory posture, benefiting from Canada's established framework and delivering a clean enforcement record. This regulatory clarity lifts the pillar to 65.5, the firmest contributor to the overall profile. However, fundamentals remain challenged at 53.08. Revenue contracted 7.8 percent year-over-year while gross margin stands at 27.7 percent—modest but insufficient to offset an operating margin of negative 52.7 percent. Positive EBITDA provides cash runway stability and supports a market capitalization near $546 million, yet the combination of shrinking top-line growth and ongoing operating losses constrains the upside case.
Market dynamics present a more acute concern, scoring only 40.0 due to unavailable quote data, which signals either delisting risk or severe illiquidity that complicates price discovery and investor access. Editorial coverage registers at 30.0 with zero newsroom or brief mentions, indicating Tilray has drifted from the attention economy that often catalyzes sector re-ratings. The low conviction score of 1 out of 5 underscores the narrow margin between competing factors: regulatory tailwinds versus fundamental execution gaps and market invisibility.
The most critical signal to monitor is whether Tilray can stabilize or reverse revenue decline in the next two quarters, as any sustained top-line momentum would tighten operating losses and potentially restore market confidence, lifting the composite score toward the Overweight threshold.
- IR / PR agency
- Prosek Partners
- IR email
- investors@tilray.com
- IR page
- Investor relations
- Headquarters
- 655 MADISON AVENUE, 19TH FLOOR, NEW YORK, NY, 10065
- Phone
- 519.322.8800
- CEO
- Irwin D. Simon
- CFO
- Carl Merton
- SEC CIK
- 1731348
- Website
- Company website
- Market cap
- $545.7M
- Enterprise value
- $641.6M
- Price to book
- 0.35
- Price to sales
- 0.64
- EV / EBITDA
- -4.84
- Revenue (TTM)
- $858.3M
- Gross profit (TTM)
- $237.6M
- EBITDA
- $17.8M
- Operating margin
- -52.7%
- Profit margin
- -156.7%
- Rev growth YoY
- -7.8%
- Return on equity
- -63.2%
- Return on assets
- -1.5%
- EPS (TTM)
- $-14.63
- EPS est. current year
- $-0.11
- Wall St. target price
- $9.55
- Shares outstanding
- 123.5M
- Insider ownership
- 0.7%
- Institutional ownership
- 9.4%
- Beta
- 1.90
- Full-time employees
- 2,842
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Annual report
- Latest 10-K
- Proxy statement
- Latest DEF 14A
- Filing portal
- SEDAR+
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for Tilray Brands (TLRY)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Tilray Brands (TLRY), a cannabis-sector equity listed on NASDAQ in the Canadian LP category. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
Analyst average price target $7.47.
CIN editorial stance: Event-Driven Opportunity. Setup improving. Strong session detected. (5 bullish signals, 3 bearish signals.)
Global cannabis and consumer goods company. Largest cannabis company by revenue globally with operations in 20+ countries.
Latest price: $4.54 (+8.10%) on NASDAQ.
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for TLRY are maintained by Cannabis Investor News and refreshed throughout the trading day.